<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="old Cameroonian, previously exposed to raltegravir, and failing on third-line" exact="treatment" post="with multi-drug resistance to darunavir/r and dolutegravir. Genotypic resistance"/>
 <result pre="treatment with multi-drug resistance to darunavir/r and dolutegravir. Genotypic resistance" exact="testing" post="(GRT) and viral tropism were performed during monitoring time"/>
 <result pre="where drug options are limited, poor adherence is frequent, and" exact="treatment" post="monitoring (viral load essentially) remains sub-optimal [1, 2]. ART"/>
 <result pre="launched in Cameroon by May 2003, and genotyping drug resistance" exact="testing" post="(GRT) is recommended essentially after failing a PI/r-based regimen"/>
 <result pre="to August 2009. From August 2009, the patient voluntarily stopped" exact="treatment" post="and returned to the clinic in 2010 for consultation."/>
 <result pre="(87 cells/mm3). Prior to ART re-initiation in 2010, genotypic resistance" exact="testing" post="(GRT) results, interpreted throughout using Stanford HIVDB (http://www.hivdb.stanford.edu) and"/>
 <result pre="accordingly, classified as WHO clinical stage 3. After completing anti-tuberculosis" exact="treatment" post="in 2012, he was lost to follow-up (duration unclear)"/>
 <result pre="which adherence was suboptimal (assessed by self-reporting). While completing anti-tuberculosis" exact="treatment" post="the patient discontinued HIV-treatment. Following clinical assessment, he was"/>
 <result pre="Following intensified/close adherence strategy implemented, the patient is compliant to" exact="treatment" post="but the latest plasma viral load remains high, with"/>
 <result pre="positive rate GP 120 Envelope glycoprotein 120 GRT Genotypic resistance" exact="testing" post="HIV Human immunodeficiency virus HIVDR HIV drug resistance IN"/>
 <result pre="antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant" exact="diagnosis" post="of HIV - Interim guidance: Who; 2018. https://www.who.int/hiv/pub/guidelines/ARV2018update/en/. 4.AchiengLRiedelDJDolutegravir"/>
 <result pre="of Dolutegravir in treatment-experienced subjects with Raltegravir-resistant HIV type 1" exact="infection" post=": 24-week results of the VIKING study. J Infect"/>
 <result pre="HIV Med20161713510.4102/sajhivmed.v17i1.454 14.SeatlaKKAvalosAMoyoSet al.Four-class drug-resistant HIV-1 subtype C in a" exact="treatment" post="experienced individual on dolutegravirbased antiretroviral therapy in BotswanaAids.201832131899190210.1097/QAD.000000000000192029894383 15.PenaMJChuecaNDâ€™AvolioAZarzalejosJMGarciaFVirological"/>
 <result pre="infectionNat Commun201891192810.1038/s41467-018-04217-529765018 18.CharlesKMireilleM-EPierretteOBet al.Dolutegravir-based or low-dose Efavirenzâ€&quot;based regimen for the" exact="treatment" post="of HIV-1N Engl J Med2019381981682610.1056/nejmoa190434031339676"/>
</results>
